Latest Breaking News On - Danielj george - Page 1 : vimarsana.com

What Patients Can Do as Racial Disparities Persist in Prostate Cancer

Patient/provider trust, education and lifestyle choices are crucial as Black men face higher incidence and mortality in prostate cancer, experts said.

United statesDanielj georgeShiba khanFred hutchinson cancer centerAmerican cancer societySchool of medicine at duke universityEleanor easley distinguished professorProstate cancerRacial disparities

SESAUA 2024: Association of PSA Response and Overall Survival in Patients with mHSPC: Results from the Phase 3 ARASENS Trial

SESAUA 2024: Association of PSA Response and Overall Survival in Patients with mHSPC: Results from the Phase 3 ARASENS Trial
urotoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from urotoday.com Daily Mail and Mail on Sunday newspapers.

United statesDanielj georgeDaniel georgeZachary klaassenSoutheastern section of the american urological associationGeorgia cancer centerDuke cancer instituteUrologic oncologistAssociate professorAmerican urological associationAnnual meetingMonth prostate specific antigenAndrogen deprivationProstate specific antigen kineticsOverall survivalRadiological progression free survival

Dr George on the CheckMate 8Y8 Trial of Nivolumab With/Without Ipilimumab in Untreated RCC

Daniel J. George, MD, discusses the phase 3b CheckMate 8Y8 study of nivolumab plus ipilimumab vs nivolumab alone in previously untreated advanced RCC

Danielj georgeEuropean medicines agencyDuke cancer institutePhase 3b checkmate 8y8 study nct03873402Dvanced renal cell carcinomaAsco gu

Real-World Findings Emphasize the Need for Early Genetic Testing in HRR-Mutated mCRPC

Patients with HRR gene–mutated mCRPC treated with olaparib have an unmet need for early and consistent genetic testing to optimize treatment outcomes.

Duke universityNorth carolinaUnited statesDanielj georgeDuke university school of medicineDuke university schoolPatients with homologous recombination repair mutated metastatic castration resistant prostate cancer2024 genitourinary cancers symposium

Dr Daniel J George Discusses the Use of Biomarkers in RCC Treatment

While there are reliable biomarkers to monitor disease progression and guide treatment decisions for tyrosine kinase inhibitors in renal cell carcinoma (RCC), there is a need for biomarkers for immunotherapies.

Duke universityNorth carolinaUnited statesDanielj georgeDuke university school of medicineMember of the duke cancer instituteDuke cancer instituteDuke university schoolAmerican journal